Salipro Biotech Receives European Patent

Salipro Biotech Receives European Patent

By, Admin 18 March 2024

Salipro Biotech receives European patent entitled Production of Salipro particles

Overview

Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech’s growing patent portfolio: European Patent EP 3 955 895 B1, entitled “Production of Salipro particles”. This patent covers processes related to the Salipro platform and represents a pivotal milestone that strengthens Salipro Biotech’s position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters.

Words from Leaders: Salipro Biotech

  • From CEO

“We are excited about this advancement on our intellectual property portfolio and the Salipro platform technology. This patent further solidifies our position by complementing our foundational and subsequent patents that have already been granted in many countries, including US, EU, China and Japan” says Jens Frauenfeld, CEO of Salipro Biotech. “This is another significant milestone for Salipro Biotech in building a robust patent portfolio that protects our unique platform technology and supports our commitment to make the undruggable druggable.”

  • From BDD

“We are actively forging more collaborations and licensing deals with leading pharmaceutical companies across a broad spectrum of complex drug targets.” says Peter Jahnmatz, Business Development Director at Salipro Biotech. “By further strengthening our robust patent portfolio, we enhance the value proposition for our partners in these collaborations and advance the development of next-generation therapeutics against previously inaccessible drug targets.”

Patent Aapproval Impacts

  • This patent is based on one of multiple patent filings of Salipro Biotech since 2016.
  • The grant of the European patent will provide Salipro Biotech’s unique platform technology with a broader protection, further strengthening its patent portfolio to address unmet medical needs and accelerate drug discovery programs against undruggable targets.

About Salipro Biotech AB

  • Salipro Biotech AB, headquartered in Stockholm, Sweden, is a privately held biotech company committed to unlocking challenging drug targets for the development of next-generation therapeutics.
  • With a fully owned intellectual property portfolio encompassing the Salipro platform technology, the company has established multiple research collaborations with leading pharmaceutical and biotech companies worldwide.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!